VivoSeq
Other

IPEX

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

IPEX is an early-stage landscape with 0 programs across 2 companies. The most active players are Knopp Biosciences, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Knopp Biosciences

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Recruiting2 · 12%
Terminated2 · 12%

Clinical Trials

Trial Activity

17 trials

CD4^LVFOXP3 in Participants With IPEX
Recruiting·—·Phase 1·NCT05241444·30 enrolled
Pramipexole to Enhance Social Connections
Recruiting·UUniversity of California, San Diego·Phase 2·NCT06269146·108 enrolled
Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg
Completed·DDexa Medica Group·N/A·NCT02660060·23 enrolled
Pramipexole Conversion to Ropinirole Controlled Release (CR)
Completed·RRajesh Pahwa, MD·Phase 3·NCT00275275·61 enrolled
Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02264132·24 enrolled
Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT01214109·24 enrolled
Dexpramipexole SAD/MAD Study
Completed·KKnopp Biosciences·Phase 1·NCT01449578·63 enrolled
Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT01119443·28 enrolled
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
Completed·—·Phase 4·NCT00344994·20 enrolled
Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects
Completed·KKnopp Biosciences·Phase 1·NCT01607034·24 enrolled
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Completed·—·Phase 2·NCT00893841·96 enrolled
Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02261090·14 enrolled
Phase 3 Study of Dexpramipexole in ALS
Completed·KKnopp Biosciences·Phase 3·NCT01281189·942 enrolled
Dexpramipexole Renal PK Study
Completed·KKnopp Biosciences·Phase 1·NCT01424176·36 enrolled
Dexpramipexole Japanese PK Study
Completed·KKnopp Biosciences·Phase 1·NCT01424163·57 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)